Suppr超能文献

使用非放射性示踪剂评估大鼠脑中单胺氧化酶 A 和 B 型酶的占有率。

Evaluation of monoamine oxidase A and B type enzyme occupancy using non-radiolabelled tracers in rat brain.

机构信息

Discovery Research, Suven Life Sciences Ltd, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad, India.

出版信息

Neurochem Int. 2021 May;145:105006. doi: 10.1016/j.neuint.2021.105006. Epub 2021 Feb 24.

Abstract

Monoamine oxidase (MAO) enzymes, type A and B metabolise the amine neurotransmitters of the body. Selective inhibition of either enzyme is an approach for treating neurodegenerative and stress-induced disorders, and inhibition of an enzyme is proportional to the binding of the MAO inhibitor. Conventionally, the binding of test compounds to enzymes is assessed by radiolabelled ligands in ex vivo and in vivo occupancy assays. Regulatory restrictions and turnaround time are the limitations of the methods that use radiolabelled ligands. But the use of non-radiolabelled tracers and sensitive mass spectrometry (LC-MS/MS) based assays accelerated the determination of target occupancy in pre-clinical species. A report on use of non-radiolabelled ligand in in vivo MAO occupancy assay is not available. The objectives of the present study were to optimise non-radiolabelled harmine and deprenyl as selective tracers in MAO-A and MAO-B occupancy assays and evaluate MAO occupancy of test compounds in rat brain. Tracer optimisation resulted in a detectable, stable, and low ratio (<3.0) of tracer concentrations between any two brain tissues. In occupancy assay, tracer was intravenously administered (10 μg/kg, harmine or 60 μg/kg, L-deprenyl) after the treatment with test compound (clorgyline or tranylcypromine or pargyline or phenelzine or thioperamide). Specific brain tissues were isolated at a defined interval and tracer concentrations were quantified using LC-MS/MS method. Pre-treatment with MAO inhibitors resulted in a decrease (maximum, 80-85%) in harmine or an increase (maximum, 85-300%) in L-deprenyl concentrations. But we considered the change in tracer concentration, relative to the vehicle and positive control groups to calculate MAO occupancy. The observed selectivity and ratio of occupancies (ED) of test compound towards MAO-A and MAO-B are comparable with the results from in vitro radiolabelled ligand-based inhibition assay. The results demonstrated the application of these non-radiolabelled tracers as suitable pre-clinical tools to determine MAO occupancy.

摘要

单胺氧化酶(MAO)酶 A 和 B 代谢体内的胺类神经递质。选择性抑制任一种酶都是治疗神经退行性和应激诱导障碍的方法,而对一种酶的抑制与 MAO 抑制剂的结合成正比。传统上,通过放射性标记配体在离体和体内占有率测定来评估测试化合物与酶的结合。放射性标记配体方法的限制因素是监管限制和周转时间。但是,使用非放射性示踪剂和灵敏的质谱(LC-MS/MS)基于测定法加速了临床前物种中靶标占有率的确定。目前尚无关于非放射性配体在体内 MAO 占有率测定中的应用报告。本研究的目的是优化非放射性标记的 harmine 和 deprenyl 作为 MAO-A 和 MAO-B 占有率测定中的选择性示踪剂,并评估测试化合物在大鼠脑中的 MAO 占有率。示踪剂优化导致可检测、稳定且示踪剂浓度在任何两种脑组织之间的比值(<3.0)低。在占有率测定中,在给予测试化合物(氯丙嗪、曲尼司特、帕吉林、苯乙肼或噻哌酰胺)后,经静脉内给予示踪剂(10μg/kg,harmine 或 60μg/kg,L-去甲替林)。在定义的时间间隔内分离特定的脑组织,并使用 LC-MS/MS 方法定量示踪剂浓度。MAO 抑制剂预处理导致 harmine 浓度降低(最大,80-85%)或 L-去甲替林浓度增加(最大,85-300%)。但是,我们考虑示踪剂浓度相对于载体和阳性对照组的变化来计算 MAO 占有率。观察到的测试化合物对 MAO-A 和 MAO-B 的选择性和占有率(ED)比值与基于体外放射性标记配体抑制测定的结果相当。结果表明,这些非放射性示踪剂可作为确定 MAO 占有率的合适临床前工具。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验